Your browser doesn't support javascript.
loading
Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.
Leussink, Verena Isabell; Jankovic, Manda; Groth, Marie; Schuh, Katrin; Sauerbeck, Inessa Schwab; Hoffmann, Olaf.
Affiliation
  • Leussink VI; Praxis Neurologie in Meerbusch, Meerbusch, Germany.
  • Jankovic M; Sauerlandklinik Hachen, Sundern, Germany.
  • Groth M; Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
  • Schuh K; Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
  • Sauerbeck IS; Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.
  • Hoffmann O; St. Josefs-Krankenhaus Potsdam-Sanssouci, Potsdam, Germany.
Brain Behav ; 14(6): e3548, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38841819
ABSTRACT

BACKGROUND:

The revised Lublin classification offers a framework for categorizing multiple sclerosis (MS) according to the clinical course and imaging results. Diagnosis of secondary progressive MS (SPMS) is often delayed by a period of uncertainty. Several quantitative magnetic resonance imaging (qMRI) markers are associated with progressive disease states, but they are not usually available in clinical practice.

METHODS:

The MAGNON project enrolled 629 patients (early relapsing-remitting MS (RRMS), n = 51; RRMS with suspected SPMS, n = 386; SPMS, n = 192) at 55 centers in Germany. Routine magnetic resonance imaging (MRI) scans at baseline and after 12 months were analyzed using a centralized automatic processing pipeline to quantify lesions and normalized brain and thalamic volume. Clinical measures included relapse activity, disability, and MS phenotyping. Neurologists completed questionnaires before and after receiving the qMRI reports.

RESULTS:

According to the physicians' reports, qMRI results changed their assessment of the patient in 31.8% (baseline scan) and 27.6% (follow-up scan). For ∼50% of patients with RRMS with suspected SPMS, reports provided additional information that the patient was transitioning to SPMS. In >25% of all patients, this information influenced the physicians' assessment of the patient's current phenotype. However, actual changes of treatment were reported only in a minority of these patients.

CONCLUSIONS:

The MAGNON results suggest that standardized qMRI reports may be integrated into the routine clinical care of MS patients and support the application of the Lublin classification as well as treatment decisions. The highest impact was reported in patients with suspected SPMS, indicating a potential to reduce diagnostic uncertainty.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Magnetic Resonance Imaging / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Relapsing-Remitting Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Brain Behav / Brain and behavior (Online) Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Magnetic Resonance Imaging / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Relapsing-Remitting Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Brain Behav / Brain and behavior (Online) Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United States